Losartan Potassium Tablet, Film Coated
Product Images NDC 43063-955

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 43063-955). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063955 Label (43063955)

Label for Losartan Potassium USP 50 mg film-coated tablets, containing 90 tablets per bottle, labeled by PD-Rx Pharmaceuticals, Inc. NDC 43063-955-90. The label includes medication details, dosage strength, quantity, a warning to keep out of reach of children, expiration date 07/2021, lot number G19F15, and reorder number 110768. The label also features barcodes and a QR code.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients reaching a primary endpoint over a 66-month study period for Losartan Potassium versus Atenolol. The graph shows a continuous increase in event rates with Atenolol depicted by a dotted line and Losartan Potassium by a solid line. It notes an adjusted risk reduction of 13% with Losartan Potassium, with a p-value of 0.021.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period for Atenolol and Losartan Potassium. The y-axis shows the percentage of patients, and the x-axis shows study months. The graph indicates an adjusted risk reduction of 25% for Losartan Potassium with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 displays two forest plots comparing primary endpoint events and stroke outcomes between Losartan Potassium and Atenolol across demographic subgroups. It includes hazard ratios with 95% confidence intervals for age, gender, race, ISH, diabetes, and history of cardiovascular disease, showing event rates and favorability toward each drug.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph depicting the percentage of patients with an event over 48 months comparing Losartan Potassium versus placebo. The graph shows a lower event rate for Losartan Potassium with a reported risk reduction of 16.1% and a significance level of p=0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure diagram of Losartan Potassium, showing the molecular arrangement including the tetrazole ring, biphenyl group, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.